Trump’s possible IVF action an incremental positive for Progyny, says BofA

BofA reiterated a Buy rating and $30 price target on Progyny (PGNY) after media reported that President Trump is set to announced a new policy initiative aimed at further expanding access to in vitro fertilization. The news is an incremental positive for Progyny, but the actual impact may be more nuanced, the analyst tells investors in a research note. The firm noted the spotlight around IVF is a positive for awareness and may drive some demand for coverage in certain pockets of employers. Given Progyny is a market leader with broad geographic coverage, the company appears well positioned to capture upside if there is in fact a benefit to coverage and utilization, the analyst adds.